SAN DIEGO – A new analysis of a large-scale trial of a novel lipid-lowering agent has shown a particularly large reduction in cardiovascular events in the primary prevention population enrolled in the ...

Please provide your email address to receive an email when new articles are posted on . PCSK9 inhibition demonstrated benefit in the broader primary prevention population for LDL lowering and plaque ...

Even though hyperlipidemia heightens vulnerability to MIs and strokes, clinicians are not doing a very good job controlling the condition. Less than half of all patients who qualify for lipid-lowering ...

The use of aspirin for primary prevention has significantly declined in recent years following changes to clinical guidelines, with drop-offs seen in older adults as well as those with a low 10-year ...